Accessibility Menu
Gri Bio logo

Gri Bio

(NASDAQ) GRI

Current Price$1.62
Market Cap$2.73MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2023)-100%
5 Year-100%
1 Year-97%
1 Month-29%
Gri Bio last closing stock price
MetricPriceDate
Last closeUSD 1.542026-07-16
Gri Bio stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-13.48%USD 1.782026-07-09
1 month-29.03%USD 2.172026-06-16
3 month-39.61%USD 2.552026-04-17
Year to date-77.71%USD 6.912025-12-31
1 year-97.34%USD 57.962025-07-16
3 year-100%USD 164,167.642023-07-17
5 year-100%USD 6,640,342.802021-07-16
Since inception-100%USD 371,867.182023-04-24

Gri Bio Financials at a Glance

Market Cap

$2.73MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$10.91M

EPS (TTM)

-$79.55

P/E Ratio

-0.02

Dividend

$0.00

Beta (Volatility)

1.04 (Average)

Price

$1.62

Volume

1

Open

$1.65

Previous Close

$1.54

Daily Range

$1.53 - $1.65

52-Week Range

$1.53 - $80.36

Estimated Earnings Date

Aug 13, 2026

GRI News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Gri Bio

GRI Bio develops medicines for people with immune system diseases. Its main drugs aim to help those with lung and autoimmune problems. The company’s treatments target the body’s immune response to reduce harmful inflammation.

What’s in the Medicine Cabinet?

  • GRI-0621 (Lead Drug): Oral treatment for severe lung scarring (idiopathic pulmonary fibrosis).
  • GRI-0803: Early-stage oral drug for autoimmune diseases like lupus; no revenue yet.
  • GRI-0124 and GRI-0729: Compounds to balance immune system activity; preclinical stage, no revenue.
  • Compound Library: Over 500 chemical compounds for future drug development; not yet commercialized.

Growth Spurts and Science Experiments

  • Started Phase 2a trial for GRI-0621 in December 2023 in the US.
  • Filed to expand GRI-0621 trials to the UK and Australia in 2024.
  • Planned first human trial for GRI-0803 in 2025.
  • Raised $11.8 million in 2024 through equity offerings and warrant exercises.

Why GRI Bio Marches to Its Own Beat

GRI Bio focuses on rare immune diseases with few treatment options. It owns all rights to its drug candidates and patents. The company relies on outside partners for manufacturing and clinical trials.

Five Things You Need to Know

  • Revenue was $6 million in QQ3 2025, first reported after two years at $0.
  • Net loss was $3 million in QQ3 2025, which increased by 58% compared to QQ3 2024.
  • Cash used in operations was $-2 million in QQ3 2025, down 2% year-over-year.
  • Cash and equivalents were $5 million as of December 31, 2024.
  • Three full-time employees and one part-time staff as of March 2025.

Bottom Line

GRI Bio is a small biotech firm focused on immune-related diseases. It remains early-stage, with new revenue and ongoing clinical trials shaping its future.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

4

CEO

W. Marc Hertz, PhD

Website

www.gribio.com

Headquarters

La Jolla, CA 92037, US

GRI Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-199.52%

Return on Capital

-197.02%

Return on Assets

-96.20%

Earnings Yield

-50.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.73MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.77M

Volume

1

Avg. Volume

66.68K

Financials (TTM)

Gross Profit

-$4.00K

Operating Income

-$10.93M

EBITDA

-$10.92M

Operating Cash Flow

-$12.14M

Capital Expenditure

-$3.00K

Free Cash Flow

-$12.14M

Cash & ST Invst.

$11.05M

Total Debt

$58.00K

Gri Bio Performance Analysis

Gri Bio annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Gri Bio sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-07-31N/A
Q32025-10-31N/A
Q42026-01-31N/A
Q12026-03-31N/A
Gri Bio annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -4,629,696.38160.9%
20232023-12-31USD -174,780.93-96.2%
20242024-12-31USD -1,545.77-99.1%
20252025-12-31USD -121.80-92.1%
Gri Bio sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-07-3177.4%
Q32025-10-312.3%
Q42026-01-3185.1%
Q12026-03-3169.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$1.00K

+0.0%

Gross Margin

0.00%

N/A

Market Cap

$2.73MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$681.78K

N/A

Employees

4

N/A

Net Income

-$2.00M

+34.4%

EBITDA

-$2.00M

+34.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$11.05M

+236.7%

Total Debt

$58.00K

-46.3%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$58.00K

+16.0%

Return on Assets

-96.20%

N/A

Return on Invested Capital

-1.04%

N/A

Free Cash Flow

-$3.69M

-72.8%

Operating Cash Flow

-$3.69M

-112.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CNSPCNS Pharmaceuticals, Inc.
$4.74+1.28%
INMInMed Pharmaceuticals Inc.
$1.59+0.00%
BDRXBiodexa Pharmaceuticals Plc
$2.13-4.91%
SXTP60 Degrees Pharmaceuticals, Inc.
$1.52-1.94%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$10.36-0.08%
NVDANvidia
$207.33-0.02%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$27.51-0.12%
INTCIntel
$96.83-0.06%

Questions About GRI

What is the current price of Gri Bio?

Gri Bio is trading at $1.54 per share.

What is the 52-week range for Gri Bio?

Over the past 52 weeks, Gri Bio has traded between $1.53 and $80.36.

How much debt does Gri Bio have?

As of the most recent reporting period, Gri Bio reported total debt of $58.00K.

How much cash does Gri Bio have on hand?

Gri Bio reported $11.05M in cash and cash equivalents in its most recent financial results.

What is Gri Bio’s dividend yield?

Gri Bio does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services